Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
DT-168 · 1 trial · 2 indications
Assessment of DT-168 on splicing patterns in genes that are known to be disrupted in FECD.
| Arm | Type | Description |
|---|---|---|
| Active | EXPERIMENTAL | Drug: DT-168 |
| Name | Type | Description |
|---|---|---|
| DT-168 | DRUG | Active |
Inclusion Criteria: * Participant is scheduled to undergo a keratoplasty for management of FECD independent of this study. * ≥30 years of age (inclusive). * Documented diagnosis of FECD in the study eligible eye. * Confirmation of positive TCF4 allele 18.1 CTG expansion in at least one allele. * Ca...
DT-168 is an investigational small molecule being developed for Fuchs Endothelial Corneal Dystrophy, an eye condition affecting the cornea. It is in Phase 2 clinical development and is not yet approved for any use. The current study enrolls patients with Fuchs Endothelial Corneal Dystrophy who are undergoing keratoplasty.
DT-168 targets TCF4, a transcription factor. By acting on TCF4, the small molecule is designed to address the underlying cause of Fuchs Endothelial Corneal Dystrophy. This targeted approach distinguishes it from symptomatic treatments for the condition.
DT-168 is being developed by Design Therapeutics, Inc., a biopharmaceutical company traded on the Nasdaq under the ticker DSGN. The company is focused on small molecule therapeutics for serious degenerative diseases, and DT-168 is its investigational candidate for Fuchs Endothelial Corneal Dystrophy.
DT-168 is in Phase 2 clinical development. The only trial listed is a Phase 2 study that is currently recruiting participants. There are no completed trials for DT-168, and the drug remains investigational.
DT-168 is being evaluated in a single Phase 2 trial, NCT07024693, titled "DT-168 in Keratoplasty Patients With Fuchs Endothelial Corneal Dystrophy." The study is recruiting 70 participants in the United States. It is an uncontrolled trial, meaning it does not have a placebo or active comparator arm.